Therefore, in this study, we evaluated the clinical characteristics and tumor immune microenvironment according to this refined HER2 classification in HER2-negative breast cancer patients treated with neoadjuvant chemotherapy (NAC), and retrospectively analyzed their therapeutic effect and prognosis. This evidence concerns the gene ERBB2 and neoplasm.